Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.

Delivering cures for neurodegenerative diseases. 

​​Lysosomal Therapeutics Inc.​​

Neurons, Lysosomes and  Disease

Proteins accumulate due to errors in lysosome function, resulting in the damage of neurons. Damaged neurons degenerate and die causing a loss in cognitive, sensory and motor function in common diseases such as Parkinson's and rare diseases such as Gaucher's. LTI is leveraging its world-class knowledge of lysosomal biology and drug development to deliver innovative agents for neurodegenerative disease.